Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helps with early hair regrowth in people with alopecia areata.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.

Alopecia areata was successfully treated with contact immunotherapy, oral antihistamines, and topical corticosteroids.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.

The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

A group has developed therapies that show promise for treating cancer and various other conditions.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

More effective methods are needed to prevent hair loss from chemotherapy.

Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.